Malignant tumors of the hepatobiliary system
Conditions
Interventions
Index test:Imaging: Computed Tomography. Pathology: Histopathology, immunohistochemistry (IHC), and molecular pathology. Blood biochemical parameters: Albumin/Globulin ratio, ALP, Prealbumin, Direct b
Sponsors
Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Pathological diagnosis: All subjects must be pathologically confirmed and provide clear histological evidence. Patients with malignant tumors must have complete pathological staging information according to the AJCC 8th edition TNM staging system; 2. Age requirements: Subject age >=18 years old, gender is not limited. Considering that hepatobiliary malignancies are more common in the elderly population, there is no upper age limit to ensure the representativeness of the sample; 3. Complete imaging data: complete preoperative imaging examination data, including multi-stage CT or MRI image data, and the image quality meets the analysis requirements; 4. Complete pathological data: complete postoperative pathological sections and WSI digital pathological data, clear H&E staining, suitable for deep learning analysis; 5. Complete clinical data: complete clinical data such as clinical examination data, surgical records, diagnosis and treatment; 6. Follow-up information is available: The patient's prognosis information can be obtained through the hospital system or follow-up, including survival status, recurrence and metastasis, etc.
Exclusion criteria
Exclusion criteria: 1.Concurrent presence of two or more malignant tumors, or hepatobiliary malignant tumor lesions that are non-primary (metastatic) lesions; 2.Comorbid severe central nervous system diseases, respiratory system diseases, autoimmune diseases, chronic renal insufficiency, or other diseases; long-term use of immunosuppressive agents; comorbid severe uncontrolled infections; 3.Concurrent active cardiovascular and cerebrovascular diseases, including cerebrovascular accident, myocardial infarction, or unstable angina within 6 months; congestive heart failure of Class II or above according to New York Heart Association (NYHA) criteria; severe arrhythmias requiring pharmacological treatment; 4.Women of childbearing age with positive blood pregnancy tests or who have not undergone pregnancy testing; pregnant or lactating women; 5.Patients who participated in other therapeutic clinical trials with unclear treatment measures or from which treatment information cannot be collected during their illness period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sensitivity;Specificity;Accuracy; | — |
Secondary
| Measure | Time frame |
|---|---|
| Prealbumin;Albumin/Globulin Ratio;Carcinoembryonic Antigen;Direct Bilirubin;Carbohydrate Antigen 15-3;Alkaline Phosphatase;Carbohydrate Antigen 19-9;Carbohydrate Antigen 125;Total Bilirubin;Alpha-Fetoprotein; | — |
Countries
China
Contacts
Public ContactLi Maolan
Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine
Outcome results
None listed